Neonatal Procalcitonin Intervention Study (NeoPInS): Effect of Procalcitonin-guided decision making on duration of antibiotic therapy in suspected neonatal early-onset sepsis: A multi-centre randomized superiority and non-inferiority Intervention Study

Martin Stocker, Wim C J Hop, Annemarie M C van Rossum, Martin Stocker, Wim C J Hop, Annemarie M C van Rossum

Abstract

Background: Early diagnosis and treatment of the newborn infant with suspected sepsis are essential to prevent severe and life threatening complications. Diagnosis of neonatal sepsis is difficult because of the variable and nonspecific clinical presentation. Therefore, many newborns with nonspecific symptoms are started on antibiotic treatment before the presence of sepsis has been proven. With our recently published single-centre intervention study we were able to show that Procalcitonin determinations allowed to shorten the duration of antibiotic therapy in newborns with suspected early-onset sepsis.

Methods/design: The study is designed as randomized controlled international multicenter intervention trial on the efficacy and safety of Procalcitonin guided treatment. Term and near-term infants (gestational age ≥ 34 0/7 weeks) with suspected sepsis in the first 3 days of life requiring empiric antibiotic therapy will be included. The duration of antibiotic therapy in the standard group is based on the attending physician's assessment of the likelihood of infection (infection unlikely, possible, probable or proven). In the Procalcitonin group, if infection is considered to be unlikely or possible, antibiotic therapy is discontinued when two consecutive Procalcitonin values are within the normal range. Co-primary outcome measures are the duration of antibiotic therapy (superiority aspect of the trial) and the proportion of infants with a recurrence of infection requiring additional courses of antibiotic therapy and/or death in the first month of life (safety of study intervention, non-inferiority aspect of the trial). The number of infants to be included equals 800 per arm. With these numbers the power of the study to demonstrate superiority for duration of antibiotic therapy as well as non-inferiority regarding safety, i.e. excluding a disadvantage difference larger than 2% for the experimental arm, will both be greater than 80%.

Discussion: Benefit of the study is a possible limitation of unnecessary use of antibiotics. The results of our first study suggest that there is a low risk on discontinuing antibiotic treatment too early, resulting in the development of a neonatal infection with its morbidity and mortality.

Trial registration: This trial is registered in the U.S. National Institutes of Health's register, located at http://www.clinicaltrials.gov. (NCT00854932).

Figures

Figure 1
Figure 1
Normal age-adapted PCT ranges. Grey boxes = age-adapted normal range [47].

References

    1. Sankar MJ, Agarwal R, Deorari AK, Paul VK. Sepsis in the newborn. Indian J Pediatr. 2008;75(3):261–266. doi: 10.1007/s12098-008-0056-z.
    1. Gladstone IM, Ehrenkranz EA, Edberg SC, Baltimore RS. A ten year review of neonatal sepsis and comparison with the previous fifty-year experience. Pediatr Infect Dis J. 1990;9(11):819–890. doi: 10.1097/00006454-199011000-00009.
    1. Bizarro MJ, Raskind C, Baltimore RS, Gallagher PG. Seventy-five years of neonatal sepsis at Yale: 1928-2003. Pediatrics. 2005;116:595–602. doi: 10.1542/peds.2005-0552.
    1. Lawn JE, Wilczynska-Ketende K, Cousens SN. Estimating the causes of 4 million neonatal deaths in the year 2000. Int J Epidemiol. 2006;35:706–718. doi: 10.1093/ije/dyl043.
    1. Afroza S. Neonatal Sepsis - a global problem: an overview. Mymensingh Med J. 2006;15:108–114.
    1. Stoll BJ, Hansen NJ, Adams-Chapman I, Fanaroff AA, Hintz SR, Vohr B, Higgins RD. Neurodevelopmental and growth impairment among extremely low-birth weight infants with neonatal infection. JAMA. 2004;292:2357–2365. doi: 10.1001/jama.292.19.2357.
    1. van den Hoogen A, Gerards LJ, Verboon-Maciolek MA, Fleer F, Krediet TG. Long-Term Trends in the Epidemiology of Neonatal Sepsis and Antibiotic Susceptibility of Causative Agents. Neonatology. 2009;97:22–28. doi: 10.1159/000226604.
    1. Connell TG, Rele M, Cowley D, Buttery JP, Curtis N. How reliable is a negative blood culture result? Volume of blood submitted for culture in routine practice in a children's hospital. Paediatrics. 2007;119(5):891–6. doi: 10.1542/peds.2006-0440.
    1. Weinberg GA, Powel KR. In: Infectious diseases of the fetus and newborn infant. Remington JS, Klein JO, editor. Phildelphia: WB Saunders; 2001. Laboratory aids for diagnosis of neonatal sepsis; pp. 1327–1344.
    1. Al-Zwaini EJ. C-reactive protein: a useful marker for guiding duration of antibiotic therapy in suspected neonatal septicaemia? East Mediterr Health J. 2009;15(2):269–275.
    1. Couto RC, Barbosa JA, Pedrosa TM, Biscione FM. C-reactive protein-guided approach may shorten length of antimicrobial treatment of culture-proven late-onset sepsis: an intervention study. Braz J Infect Dis. 2007;11(2):240–245. doi: 10.1590/S1413-86702007000200015.
    1. Enguix A, Rey C, Concha A, Medina A, Coto D, Dieguez MA. Comparison of procalcitonin with C-reactive protein and serum amyloid for the early diagnosis of bacterial sepsis in critically ill neonates and children. Int Care Med. 2001;27:211–15. doi: 10.1007/s001340000709.
    1. Fernandez Lopez A, Luaces Cubells C, Garcia JJ, Fernandez PJ. Procalcitonin in pediatric emergency departments for the early diagnosis of invasive bacterial infections in febrile infants: results of a multicenter study and utility of a rapid qualitative test for this marker. Pediatr Infect Dis J. 2003;22:895–903. doi: 10.1097/01.inf.0000091360.11784.21.
    1. Prat C, Dominguez J, Rodrigo C, Gimenez M, Azuara M, Blanco S, ausina V. Use of quantitative and semi quantitative PCT measurements to identify children with sepsis and meningitis. Eur J Clin Microbiol Infect Dis. 2004;23:136–38. doi: 10.1007/s10096-003-1066-4.
    1. Carrol ED, Newland P, Riordan FA, Thomson AP, Curtis N, Hart CA. Procalcitonin as a diagnostic marker of meningococcal disease in children presenting with fever and a rash. Arch Dis Child. 2002;86:282–85. doi: 10.1136/adc.86.4.282.
    1. Hatherill M, Tibby SM, Sykes K, Turner C, Murdoch IA. Diagnostic markers of infection: comparison of procalcitonin with C reactive protein and leucocyte count. Arch Dis Child. 1999;81:417–21. doi: 10.1136/adc.81.5.417.
    1. Muller B, White JC, Nylen ES, Snider RH, Becker KL, Habener JF. Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab. 2000;86:396–404. doi: 10.1210/jc.86.1.396.
    1. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993;341:515–18. doi: 10.1016/0140-6736(93)90277-N.
    1. Muller B, Becker KL, Schachinger H, Rickenbacher PR, Huber PR, Zimmerli W, Ritz R. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med. 2000;28:977–83. doi: 10.1097/00003246-200004000-00011.
    1. Nylen ES, O'Neill W, Jordan MH, Snider RH, Moore CF, Lewis M, Silva OL, Becker KL. Serum procalcitonin as an index of inhalation injury in burns. Horm Metab Res. 1992;24:439–43. doi: 10.1055/s-2007-1003354.
    1. Whang KT, Steinwald PM, White JC, Nylen ES, Snider RH, Simon GL, Goldberg RL, Becker KL. Serum calcitonin precursors in sepsis and systemic inflammation. J Clin Endocrinol Metab. 1998;83:3296–3301. doi: 10.1210/jc.83.9.3296.
    1. Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M, Bohuon C. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab. 1994;79:1605–1608. doi: 10.1210/jc.79.6.1605.
    1. Brunkhorst FM, Heinz U, Forycki ZF. Kinetics of procalcitonin in iatrogenic sepsis. Intensive Care Med. 1998;24:888–89. doi: 10.1007/s001340050683.
    1. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448–54. doi: 10.1056/NEJM199902113400607.
    1. Steel DM, Whitehead AS. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today. 1994;15:81–88. doi: 10.1016/0167-5699(94)90138-4.
    1. Monneret G, Labaune JM, Isaac C, Bienvenu F, Putet G, Bienvenu J. Procalcitonin and C-reactive protein levels in neonatal infections. Acta Paediatr. 1997;86:209–12. doi: 10.1111/j.1651-2227.1997.tb08870.x.
    1. Bonac B, Derganc M, Wraber B, Hojker S. Interleukin-8 and procalcitonin in early diagnosis of early severe bacterial infection in critically ill neonates. Pflugers Arch. 2000;440:R72–74. doi: 10.1007/s004240000011.
    1. Lapillonne A, Basson E, Monneret G, Bienvenu J, Salle BL. Lack of specificity of procalcitonin for sepsis diagnosis in premature infants. Lancet. 1998;351:1211–12. doi: 10.1016/S0140-6736(05)79165-0.
    1. Chiesa C, Pellegrini G, Panero A, Osborn JF, Signore F, Assuma M, Pacifico M. C-reactive protein, interleukin-6, and procalcitonin in the immediate postnatal period: Influence of illness severity, risk status, antenatal and perinatal complications, and infection. Clin Chem. 2003;49(1):60–68. doi: 10.1373/49.1.60.
    1. Petzold L, Guibourdenche J, Boissinot C, Benoist JF, Luton D, Demelier JF, Porquet D. Determination of procalcitonin in the diagnosis of maternal-fetal infections. Ann Biol Clin. 1998;56:599–602. (French)
    1. Oberhoffer M, Stonans I, Russwurm S, Stonane E, Vogelsang H, Junker U, Jäger L, Reinhardt K. Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis-related cytokines in vitro. J Lab Clin Med. 1999;134:49–55. doi: 10.1016/S0022-2143(99)90053-7.
    1. Ugarte H, Silva E, Mercan D, De Mendonca A, Vincent JL. Procalcitonin used as a marker of infection in the intensive care unit. Crit Care Med. 1999;27:498–504. doi: 10.1097/00003246-199903000-00024.
    1. Chiesa C, Panero A, Rossi N, Stegagno M, DeGiusti M, Osborn JF, Pacifico L. Reliability of Procalcitonin concentrations for the diagnosis of sepsis in critically ill neonates. Clin Infect Dis. 1998;26:664–672. doi: 10.1086/514576.
    1. Assumma M, Signore F, Pacifico L, Rossi N, Osborn JF, Chiesa C. Serum Procalcitonin Concentrations in Term Delivering Mothers and Their Healthy Offspring: A Longitudinal Study. Clinical Chemistry. 2000;46(10):1583–1587.
    1. Enguix A, Rey C, Concha A, Medina A, Coto D, Dieguez MA. Comparison of procalcitonin with c-reactive protein and serum amyloid for the early diagnosis of bacterial sepsis in critically ill neonates and children. Intensive Care Medicine. 2001;27:211–215. doi: 10.1007/s001340000709.
    1. Franz AR, Kron M, Pohlandt F, Steinbach G. Comparison of procalcitonin with interleukin 8, C-reactive protein and differential white blood cell count for the early diagnosis of bacterial infections in newborn infants. Pediatric Infectious Diseases Journal. 1999;18:666–671. doi: 10.1097/00006454-199908000-00003.
    1. Guibourdenche J, Bedu A, Petzold L, Marchand M, Mariani-Kurdjian P, Hurtaud-Roux M, Aujard Y, Porquet D. Biochemical markers of neonatal sepsis: value of Procalcitonin in the emergency setting. Ann Clin Biochem. 2002;39:130–135. doi: 10.1258/0004563021901874.
    1. Joram N, Boscher C, Denizot S, Loubersac V, Winer N, Roze JC, Gras-Le Guen C. Umbilical cord blood procalcitonin and C-reactive protein concentrations as markers for early diagnosis of very early onset neonatal infection. Arch dis Child Fetal Neonatal Ed. 2006;91:F65–66. doi: 10.1136/adc.2005.074245.
    1. Kordek A, Giedrys-Kalemba S, Pawlus B, Podraza W, Czajka R. Umbilical cord blood serum procalcitonin concentration in the diagnosis of early neonatal infection. Journal of Perinatol. 2003;23:148–153. doi: 10.1038/sj.jp.7210885.
    1. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, Müller B. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004;363(9409):600–607. doi: 10.1016/S0140-6736(04)15591-8.
    1. Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber PR, Zimmerli W, Harbarth S, Tamm M, Muller B. Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia: A Randomized Trial. Am J Respir Crit Care Med. 2006;174(1):84–93. doi: 10.1164/rccm.200512-1922OC.
    1. Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Muller C, Huber P, Muller B, Tamm M. Antibiotic Treatment of Exacerbations of COPD: A Randomized, Controlled Trial Comparing Procalcitonin-Guidance With Standard Therapy. Chest. 2007;131(1):9–19. doi: 10.1378/chest.06-1500.
    1. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of Procalcitonin to shorten antibiotic treatment duration in septic patients. A randomized trial. Am J Respir Crit Care Med. 2008;177(5):498–505. doi: 10.1164/rccm.200708-1238OC.
    1. Hochreiter M, Köhler T, Schwelger A-M, Keck FS, Beln B, Von Spiegel T, Schröder S. Antibiotikatherapie bei operativen Intensivpatienten: Prokalzitonin zur Steuerung der Therapiedauer. Der Anaestesist. 2008;57(6):571–577. doi: 10.1007/s00101-008-1379-x. (German)
    1. Reinhart K. S-2 Leitlinien der Deutschen Sepsis-Gesellschaft e.V. (DSG) und der Deutschen Interdisziplinären Vereinigung für Intensiv- und Notfallmedizin (DIVI) 2005. (German)
    1. O'Grady NP, Barie PS, Bartlett JG, Bleck T, Carroll K, Kalil AC, Linden P, Maki DG, Nierman D, Pasculle W, Masur H. Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American College of Critical care Medicine and the Infectious Diseases Society of America. Crit Care Med. 2008;36(4):1330–1344.
    1. Stocker M, Fontana M, El Helou S, Wegscheider K, Berger TM. Effect of procalcitonin-guided decision making on duration of antibiotic therapy in suspected neonatal early-onset sepsis: prospective randomized intervention trial. Neonatology. 2010;97:165–174. doi: 10.1159/000241296.
    1. Piaggi G, Elbourne DR, Altman DG, Pocock SJ, Ewans SJ. Reporting of noninferiority and equivalence randomized trials: An extension of the CONSORT statement. JAMA. 2006;295(10):1152–1160. doi: 10.1001/jama.295.10.1152.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅